Varma Mutual Pension Insurance Co Purchases 14,700 Shares of Medtronic PLC $MDT

Key Points

• Varma Mutual Pension Insurance Co raised its Medtronic stake by 7.2% in Q4, acquiring 14,700 shares to hold 218,151 shares valued at about $20.96 million.
• Medtronic beat quarterly estimates with $1.36 EPS (vs. $1.34 expected) and $9.02 billion in revenue, and set FY2026 guidance of $5.62–$5.66 EPS (consensus ~5.57).
• The company recently paid a quarterly dividend of $0.71 (annualized $2.84), implying a yield of roughly 3.5% and a payout ratio near 79%.

Varma Mutual Pension Insurance Co grew its position in shares of Medtronic PLC (NYSE:MDT - Free Report) by 7.2% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 218,151 shares of the medical technology company's stock after acquiring an additional 14,700 shares during the quarter. Varma Mutual Pension Insurance Co's holdings in Medtronic were worth $20,956,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Curbstone Financial Management Corp boosted its position in shares of Medtronic by 1.8% during the 4th quarter. Curbstone Financial Management Corp now owns 5,594 shares of the medical technology company's stock valued at $537,000 after acquiring an additional 100 shares during the last quarter. New England Capital Financial Advisors LLC boosted its position in shares of Medtronic by 7.8% during the 4th quarter. New England Capital Financial Advisors LLC now owns 1,403 shares of the medical technology company's stock valued at $135,000 after acquiring an additional 101 shares during the last quarter. Baker Tilly Wealth Management LLC boosted its position in shares of Medtronic by 3.3% during the 4th quarter. Baker Tilly Wealth Management LLC now owns 3,221 shares of the medical technology company's stock valued at $309,000 after acquiring an additional 102 shares during the last quarter. Maseco LLP boosted its position in shares of Medtronic by 32.1% during the 4th quarter. Maseco LLP now owns 444 shares of the medical technology company's stock valued at $43,000 after acquiring an additional 108 shares during the last quarter. Finally, Holistic Financial Partners boosted its position in shares of Medtronic by 3.0% during the 3rd quarter. Holistic Financial Partners now owns 3,697 shares of the medical technology company's stock valued at $352,000 after acquiring an additional 109 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors.

Medtronic Stock Performance

NYSE:MDT opened at $80.02 on Monday. The stock's fifty day moving average is $88.44 and its 200 day moving average is $94.80. Medtronic PLC has a fifty-two week low of $78.91 and a fifty-two week high of $106.33. The firm has a market capitalization of $102.74 billion, a PE ratio of 22.29, a PEG ratio of 1.90 and a beta of 0.62. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54.

Medtronic (NYSE:MDT - Get Free Report) last released its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts' consensus estimates of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. During the same quarter last year, the firm posted $1.38 earnings per share. The business's revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts anticipate that Medtronic PLC will post 5.57 earnings per share for the current year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were paid a $0.71 dividend. The ex-dividend date was Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a yield of 3.5%. Medtronic's dividend payout ratio (DPR) is presently 79.11%.

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the sale, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. This trade represents a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.26% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on MDT. Barclays increased their target price on Medtronic from $118.00 to $120.00 and gave the company an "overweight" rating in a research report on Wednesday, April 1st. Daiwa Securities Group decreased their price target on Medtronic from $117.00 to $115.00 and set a "buy" rating on the stock in a report on Friday, February 27th. Leerink Partners restated an "outperform" rating and set a $119.00 price target on shares of Medtronic in a report on Tuesday, March 10th. UBS Group decreased their price target on Medtronic from $104.00 to $90.00 and set a "neutral" rating on the stock in a report on Wednesday, April 22nd. Finally, Robert W. Baird increased their price target on Medtronic from $92.00 to $93.00 and gave the company a "neutral" rating in a report on Wednesday, April 15th. Fifteen research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. Based on data from MarketBeat, Medtronic presently has a consensus rating of "Moderate Buy" and an average target price of $107.80.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.